Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2025

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

anti-FLT3 CAR-T

Single intravenous infusion of anti-FLT3 CAR-T cells

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

collaborator

The Second People's Hospital of Huai'an

OTHER

collaborator

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital of Soochow University

OTHER